Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
J Clin Endocrinol Metab. 2022 Jan 18;107(2):e698-e707. doi: 10.1210/clinem/dgab629.
Obesity is an established risk factor for severe COVID-19 outcomes. The mechanistic underpinnings of this association are not well-understood.
To evaluate the mediating role of systemic inflammation in obesity-associated COVID-19 outcomes.
This hospital-based, observational study included 3828 SARS-CoV-2-infected patients who were hospitalized February to May 2020 at Massachusetts General Hospital (MGH) or Columbia University Irving Medical Center/New York Presbyterian Hospital (CUIMC/NYP). We use mediation analysis to evaluate whether peak inflammatory biomarkers (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], D-dimer, ferritin, white blood cell count and interleukin-6) are in the causal pathway between obesity (BMI ≥ 30) and mechanical ventilation or death within 28 days of presentation to care.
In the MGH cohort (n = 1202), obesity was associated with greater likelihood of ventilation or death (OR = 1.73; 95% CI = [1.25, 2.41]; P = 0.001) and higher peak CRP (P < 0.001) compared with nonobese patients. The estimated proportion of the association between obesity and ventilation or death mediated by CRP was 0.49 (P < 0.001). Evidence of mediation was more pronounced in patients < 65 years (proportion mediated = 0.52 [P < 0.001] vs 0.44 [P = 0.180]). Findings were more moderate but consistent for peak ESR. Mediation by other inflammatory markers was not supported. Results were replicated in CUIMC/NYP cohort (n = 2626).
Findings support systemic inflammatory pathways in obesity-associated severe COVID-19 disease, particularly in patients < 65 years, captured by CRP and ESR. Contextualized in clinical trial findings, these results reveal therapeutic opportunity to target systemic inflammatory pathways and monitor interventions in high-risk subgroups and particularly obese patients.
肥胖是 COVID-19 重症的既定危险因素。但肥胖与这种关联的机制基础尚不清楚。
评估全身炎症在肥胖与 COVID-19 结局相关中的介导作用。
这项基于医院的观察性研究纳入了 2020 年 2 月至 5 月在马萨诸塞州综合医院(MGH)或哥伦比亚大学欧文医学中心/纽约长老会医院(CUIMC/NYP)住院的 3828 例 SARS-CoV-2 感染患者。我们使用中介分析来评估峰值炎症生物标志物(C 反应蛋白[CRP]、红细胞沉降率[ESR]、D-二聚体、铁蛋白、白细胞计数和白细胞介素-6)是否存在于肥胖(BMI≥30)与就诊后 28 天内机械通气或死亡之间的因果途径中。
在 MGH 队列(n=1202)中,肥胖与通气或死亡的可能性更大(比值比[OR]=1.73;95%置信区间[CI]=[1.25,2.41];P=0.001),并且与非肥胖患者相比,CRP 峰值更高(P<0.001)。肥胖与通气或死亡之间的关联被 CRP 介导的比例估计为 0.49(P<0.001)。在年龄<65 岁的患者中,这种中介作用更为明显(被介导的比例为 0.52[P<0.001] vs. 0.44[P=0.180])。其他炎症标志物的中介作用则不明显。在 CUIMC/NYP 队列(n=2626)中也得到了类似的结果。
这些发现支持肥胖与 COVID-19 重症之间的全身性炎症途径,特别是在年龄<65 岁的患者中,这些途径可以用 CRP 和 ESR 来捕获。在临床试验结果的背景下,这些结果揭示了针对全身炎症途径的治疗机会,并在高危亚组,特别是肥胖患者中监测干预措施。